Keep in touch

Explanatory Notes

on the Patent Status Database

Patents granted by the African Organization of Industrial Property (OAPI) are effective in all 16 OAPI member States (Benin, Burkina Faso, Cameroon, Central African Rep., Chad, Congo, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Ivory Coast, Mali, Mauritania, Niger, Senegal, and Togo). Patents granted by the African Regional Intellectual Property Organization (ARIPO) are only valid in ARIPO member States designated in the patent application, with varying expiry dates as determined by each country’s patent law (Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe).
a book with pills
Patents granted by the Eurasian Patent Organization (EAPO) are valid in the territory of the 9 Contracting States (the Republic of Armenia, the Republic of Azerbaijan, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, the Republic of Tajikistan, the Russian Federation and Turkmenistan).

Except where otherwise specified, the table provides for the expected expiry date of the relevant patents, based on a 20-year term from the filing date of the related international patent application (filed in accordance with the provisions of the Patent Cooperation Treaty or PCT). The international patent application and priority numbers are also provided to facilitate confirmation of the information at country or regional level and further search in additional countries. In cases where no international patent application was filed, the related US or European patent number and expected patent expiry date is provided.

There is a possibility that patents that appear as “Granted” and patent applications that appear as “Filed” may have expired or lapsed, or may have been withdrawn, rejected, revised, revoked or opposed. Confirmation with relevant patent authorities regarding the status of patent applications and/or maintenance of granted patents at national or regional level is therefore highly recommended.

Wherever data is considered to be preliminary in nature, particularly in cases in which it has not been cross-checked with the national/regional patent offices, it has been marked as “Preliminary.”

“Designated in Int. Applic.” means that the country has been designated in the international application filed under the World Intellectual Property Organization Patent Cooperation Treaty.

In cases where no information was available (“Unknown”), information on the patent status of the relevant medicine needs be sought from competent national or regional authorities.

A question mark “?” means there was some discrepancy between various sources.

The database provides information on the patents identified as the most important ones in relation to a specific medicine, but many other additional patents, possibly owned by different patent holders, related to new forms, new formulations or compositions, or to new manufacturing processes, may have been filed or granted.

Updates

The Medicines Patent Pool will endeavor to update and improve the table periodically. To correct any inaccuracies that may be detected in the table or to submit data that may be relevant for updating or expanding the table, please e-mail: gro.looptnetapsenicidemnull@eciffo

Acknowledgements

The Medicines Patent Pool is particularly grateful to the World Intellectual Property Organization (WIPO) for having facilitated access to information from a number of national and regional intellectual property offices and our gratitude also extends to those offices. We thank Rajeshwari Hariharan from Rajeshwari and Associates for providing the information necessary for updating the column relating to India.

The database builds upon earlier efforts at mapping patents on antiretrovirals by various organizations, including the Initiative for Medicines, Access & Knowledge (I-MAK), Médecins Sans Frontières (MSF), the UN Development Programme (UNDP) and the World Health Organization (WHO). Certain columns relied on information originally gathered by a number of experts, including Gabriela Costa Chaves, Achara Eksaengsri, Kannikar Kijtiwatchakul, Pedro Henrique Marques Villardi Miranda, and Leena Menghaney, some of whom have helped in cross-checking data. Their contributions are gratefully acknowledged.

This page is also available in: French, Spanish